---
title: Exscientia
slug: exscientia-78a98
url: /detay/exscientia-78a98
type: article
language: English
entity:
  primary: Exscientia
  type: article
  categories:
    - name: Science And Technology
      slug: bilim
      url: /kategori/bilim
    - name: Engineering
      slug: muhendislik
      url: /kategori/muhendislik
    - name: Technology And Innovation
      slug: teknoloji
      url: /kategori/teknoloji
  tags:
    - Exscientia
author: Ömer Said Aydın
created_at: 2025-10-25T21:34:10.961807+03:00
updated_at: 2025-11-04T10:42:03.799173+03:00
image: https://cdn.t3pedia.org/media/uploads/2025/10/25/7OF6AiTAlAmwqNW7jnHakGTlkj1jKcBo.webp
---

# Exscientia

<!-- CONTEXT: KURE Information Cards for "Exscientia" -->

## KURE Information Cards

![kRso2G3qkPBTqIIxJb0Jd5ISq3dVZUPK.webp](https://cdn.t3pedia.org/media/uploads/2025/10/25/vduc2ggD98guARaAcIS58SnfghL4g5Wz.webp)
*Exscientia*

| Field | Value |
|-------|-------|
| Website(s) | https://www.exscientia.ai |
| Founded(Text) | 2012 |
| Headquarters | Oxford Science Park, Oxford, United Kingdom |

<!-- CONTEXT: Article Content for "Exscientia" -->

## Article Content

**Exscientia** is a biotechnology company specializing in **AI-driven drug discovery and development**. Headquartered in the **Schrödinger Building at Oxford Science Park (UK)**, the company combines **experimental human tissue data** with **artificial intelligence analysis** to design patient-specific therapeutic candidates. [Exscientia](/en/detay/exscientia-f096e/llms.txt) integrates advanced methods such as **functional precision oncology**, **biophysical screening**, **3D structure determination**, and **high-content cellular imaging** within a unified platform.

### **Research and Development Framework**

[Exscientia](/en/detay/exscientia-baf3f/llms.txt)’s R&D infrastructure is structured around four interconnected pillars — **Precision Target**, **Precision Design**, **Precision Experiment**, and **Precision Medicine** — enabling an integrated and optimized drug discovery workflow from target identification to clinical validation.

Using **machine learning models** that integrate genetic and literature data, Exscientia identifies disease–target relationships and predicts potential patient responses using **live tissue assays**. The system prioritizes targets with **“druggable”** structural features suitable for small-molecule interaction.

The company’s proprietary **Centaur Chemist®** platform automates molecular design at the atomic and bonding level. It generates millions of 2D and 3D compounds, continuously refined through experimental feedback. The design process balances **exploration and exploitation**, optimizing for **efficacy, selectivity, safety,** and **bioavailability**.

To ensure rapid feedback between [AI](/en/detay/artificial-intelligence-in-health-ee8e4/llms.txt) models and experimental data, Exscientia operates **over 47,000 m² of laboratory space** equipped with **surface plasmon resonance (SPR)**, **X-ray crystallography**, and **transducerome** technologies. Fragment-based screening provides high-resolution binding kinetics, while structural biology techniques map ligand-binding pockets for early-stage optimization.

Through **functional precision oncology**, Exscientia has pioneered the use of **living human tissue** to predict therapeutic responses. Its **EXALT-1** clinical study demonstrated that AI-guided drug selection based on live-cell data can significantly improve patient outcomes. Single-cell profiling allows detailed evaluation of off-target effects and the therapeutic potential of each molecule.

### **Pipeline**

Exscientia’s drug development portfolio reflects its patient-centered, AI-enabled discovery model:

- **GTAEXS617 (CDK7 inhibitor)** – wholly owned; for advanced solid tumors.
- **EXS74539 (LSD1 inhibitor)** – for acute myeloid leukemia and small-cell lung cancer.
- **EXS73565 (MALT1 inhibitor)** – for hematologic malignancies.
- **EXS4318 (PKC-theta inhibitor)** – for inflammatory diseases; in Phase 1 studies.

### **Technology and Vision**

Exscientia’s integrated system unites **AI-based drug design**, **biophysical analysis**, and **human tissue testing** to accelerate discovery and enhance clinical precision. The company’s long-term goal is to transform therapeutic development through **functional precision oncology** and **molecular engineering**, enabling faster and more effective delivery of next-generation, patient-tailored treatments.

The merger between [Recursion Pharmaceuticals](/en/detay/recursion-e082d/llms.txt) and Exscientia aims to establish an integrated, global platform in AI-driven drug discovery. Recursion’s experimental biology and data infrastructure is combined with Exscientia’s AI-based molecular design and synthesis capabilities to create an end-to-end drug development system. This integration is intended to enhance research efficiency, reduce development costs, and accelerate the delivery of new therapies to patients.

<!-- CONTEXT: Academic Sources and References for "Exscientia" -->

## Academic Sources and References

1. Exscientia. “About.” LinkedIn. Accessed October 23, 2025. https://www.linkedin.com/company/ex-scientia/.Exscientia. “Pipeline.” Official Website. Accessed October 23, 2025. https://www.exscientia.com/pipeline/.Exscientia. “Precision Design.” Official Website. Accessed October 23, 2025. https://www.exscientia.com/precision-design/.Exscientia. “Precision Experiment.” Official Website. Accessed October 23, 2025. https://www.exscientia.com/precision-experiment/.Exscientia. “Precision Medicine.” Official Website. Accessed October 23, 2025. https://www.exscientia.com/precision-medicine/.Exscientia. “Precision Target.” Official Website. Accessed October 23, 2025. https://www.exscientia.com/precision-target/.